NASDAQ : JAGX
Jaguar Health, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 2.04 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 1.06M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 842,627 |
| Enterprise Value | 13.71M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 520,140 |
| Shares Outstanding | 520,140 |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +56.87% |
| Owned by Insiders (%) | 7.75% |
| Owned by Institutions (%) | 7.48% |
| Float | 437,011 |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.03 |
| Forward PS | 0.08 |
| PB Ratio | 0.08 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 0.49 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 0.74 |
| Quick Ratio | 0.17 |
| Debt / Equity | 2.53 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -25.15 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -548.83% |
| Return on Assets (ROA) | -38.04% |
| Return on Invested Capital (ROIC) | -51.73% |
| Return on Capital Employed (ROCE) | -239.75% |
| Weighted Average Cost of Capital (WACC) | 4.68% |
| Revenue Per Employee | $591,809 |
| Profits Per Employee | -$1.12M |
| Employee Count | 47 |
| Asset Turnover | 0.67 |
| Inventory Turnover | 0.55 |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | -0.11 |
| 52-Week Price Change | -99.85% |
| 50-Day Moving Average | 6.47 |
| 200-Day Moving Average | 120.09 |
| Relative Strength Index (RSI) | 39.64 |
| Average Volume (20 Days) | 3,027,179 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 140,557 |
| Short Previous Month | 84,156 |
| Short % of Shares Out | 27.02% |
| Short % of Float | 32.16% |
| Short Ratio (days to cover) | 0.02 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 27.82M |
| Gross Profit | 22.89M |
| Operating Income | -25.10M |
| Pretax Income | -36.92M |
| Net Income | -52.42M |
| EBITDA | -23.19M |
| EBIT | -25.10M |
| Loss Per Share | -$2,338.09 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 3.79M |
| Total Debt | 16.65M |
| Net Cash | -12.86M |
| Net Cash Per Share | -$24.73 |
| Equity (Book Value) | 6.57M |
| Book Value Per Share | 20.43 |
| Working Capital | -6.19M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -6.69M |
| Capital Expenditures | -41,000 |
| Depreciation & Amortization | 1.90M |
| Net Borrowing | 2.90M |
| Free Cash Flow | -6.73M |
| FCF Per Share | -$12.93 |
Margins
| Measure | Value |
|---|
| Gross Margin | 82.31% |
| Operating Margin | -90.22% |
| Pretax Margin | -132.73% |
| Profit Margin | -130.85% |
| EBITDA Margin | -83.38% |
| EBIT Margin | -90.22% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -144,326.60% |
| FCF Yield | -798.22% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | 221.30% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Sep 17, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:15 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -18.26 |
| Piotroski F-Score | 4 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |